Potential Treatment Targets for Non-alcoholic Liver Disease
A special issue of Medicines (ISSN 2305-6320).
Deadline for manuscript submissions: closed (31 October 2018) | Viewed by 9391
Special Issue Editor
Interests: nonalcoholic Fatty Liver Disease (NAFLD)
Special Issue Information
Dear Colleagues,
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome (MS) in some or may lead to MS in others and, thus, necessitates a multidisciplinary management approach. In addition, in some cases, it may not be associated with MS and presents as an isolated clinical entity. It is estimated that the global prevalence of NAFLD is over 1 billion. NAFLD affects 80 to 100 million persons in the United States, with up to 15 million developing progressive liver damage resulting in nonalcoholic steatohepatitis (NASH). NASH is the most rapidly rising indication for liver transplantation in the United States. Despite its high prevalence and a significant proportion of NAFLD cases resulting in cirrhosis followed by end-stage liver disease (liver failure), hepatocellular carcinoma, and need for liver transplantation, there are no medications approved for the treatment of NAFLD.
In this Special Issue, we attempt to systematically review current approaches and future prospects to optimize the management of NAFLD.
Prof. Dr. Aijaz Ahmed
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nonalcoholic fatty liver disease (NAFLD)
- metabolic syndrome (MS)
- nonalcoholic steatohepatitis (NASH)
- end-stage liver disease (liver failure)
- liver transplantation
- chronic liver disease